Related references
Note: Only part of the references are listed.Characterization of Recombinant Lysyl Oxidase Propeptide
Siddharth R. Vora et al.
BIOCHEMISTRY (2010)
CAS proteins in normal and pathological cell growth control
Nadezhda Tikhmyanova et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
Advanced pancreatic carcinoma: current treatment and future challenges
Anastasios Stathis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
Suee Lee et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
NIK is involved in constitutive activation of the alternative NF-κB pathway and proliferation of pancreatic cancer cells
Takashi Nishina et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
Chengyin Min et al.
CANCER RESEARCH (2009)
The Lysyl Oxidase Pro-peptide Attenuates Fibronectin-mediated Activation of Focal Adhesion Kinase and p130Cas in Breast Cancer Cells
Yingshe Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Expression of a Phosphorylated p130Cas Substrate Domain Attenuates the Phosphatidylinositol 3-Kinase/Akt Survival Pathway in Tamoxifen Resistant Breast Cancer Cells
Shefali Soni et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling
A. H. Palamakumbura et al.
ONCOGENE (2009)
Pancreatic cancer
Anirban Maitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
A Novel Association between p130Cas and Resistance to the Chemotherapeutic Drug Adriamycin in Human Breast Cancer Cells
Huy Q. Ta et al.
CANCER RESEARCH (2008)
Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells
Min Wu et al.
CANCER RESEARCH (2007)
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2
Xiaobo Wang et al.
NATURE CELL BIOLOGY (2007)
Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin
Jing Xu et al.
CANCER RESEARCH (2007)
The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer
Chengyin Min et al.
CANCER RESEARCH (2007)
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review
Ron Feld et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer
CJ Sweeney et al.
MOLECULAR CANCER THERAPEUTICS (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
The propeptide domain of lysyl oxidase induces phenotypic reversion of Ras-transformed cells
AH Palamakumbura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Lysyl Oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers
A Kaneda et al.
CANCER RESEARCH (2004)
Blocking anti-apoptosis as a strategy for cancer chemotherapy:: NF-κB as a target
NR Monks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
A Arlt et al.
ONCOGENE (2001)
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide
NM Patel et al.
ONCOGENE (2000)
Share Paper
